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A B S T R A C T   
Glucocorticoids (Gcs) potently inhibit inflammation, and regulate liver energy metabolism, often acting in a 
hypoxic environment. We now show hypoxic conditions open a specific GR cistrome, and prevent access of GR to 
part of the normoxic GR cistrome. Motif analysis identified enrichment of KLF4 binding sites beneath those peaks 
of GR binding exclusive to normoxia, implicating KLF4 as a pioneer, or co-factor under these conditions. Hypoxia 
reduced KLF4 expression, however, knockdown of KLF4 did not impair GR recruitment. KLF4 is a known target 
of microRNAs 103 and 107, both of which are induced by hypoxia. Expression of mimics to either microRNA103, 
or microRNA107 inhibited GR transactivation of normoxic target genes, thereby replicating the hypoxic effect. 
Therefore, studies in hypoxia reveal that microRNAs 103 and 107 are potent regulators of GR function. We have 
now identified a new pathway linking hypoxia through microRNAs 103 and 107 to regulation of GR function.   
1. Introduction 
Hypoxia is a condition observed in many diseases, such as inflam-
mation. The tissue response to hypoxia is dominated by the actions of 
the hypoxia-inducible factors (Moslehi and Rathmell, 2020). These 
transcription factors are stabilized at the protein level under conditions 
of low oxygen tension, and they direct an integrated response, with 
many down-stream genes showing changes in expression, and also im-
pacts on the expression of non-coding RNAs, such as the microRNAs 103 
and 107 (Kulshreshtha et al., 2007). Specifically, the HIF-1α transcrip-
tional subunit is recognized by prolyl hydroxylases and targeted for 
degradation via the Von Hippel Lindau (VHL)-mediated ubiquitin pro-
teasome pathway. Under hypoxic conditions HIF-1α is stabilized and 
translocates to the nucleus to exert its transcriptional activity. 
As the most potent anti-inflammatory agents, glucocorticoids (Gcs) 
are regularly used in clinic to treat a range of inflammatory diseases, 
such as asthma and rheumatoid arthritis. However, there remain major 
issues in the widespread use of therapeutic glucocorticoids resulting 
from insensitivity and off-target effects. It would be very useful to un-
derstand why inflammatory diseases frequently require high-dose, high 
potency glucocorticoid treatment to respond (Yang et al., 2012). One 
possible factor at sites of active inflammation is reduced oxygen tension. 
Gcs act through the ubiquitously expressed glucocorticoid receptor 
(GR), a ligand activated transcription factor and member of the nuclear 
receptor superfamily. GR function is affected by changes to the local 
tissue microenvironment (Yang et al., 2012). Therapeutically, there is 
marked variation in response to standard doses of Gc, which has been 
attributed to the expression of cytokines at the sites of inflammation 
(Ishiguro, 1999; Leung et al., 1995; Matthews et al., 2004), and also to 
the local hypoxic environment, caused by tissue pressure from edema, 
disruption of local blood supply, and increased oxygen consumption by 
infiltrating cells. Hypoxia affects local expression of cytokines, including 
IL-8 and macrophage migration inhibitory factor, but may also directly 
influence GR function. 
To date, studies defining the impact of cell hypoxia on GR function 
have been inconclusive. Hypoxic preconditioning is reported to induce 
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GR expression and increase glucocorticoid sensitivity (Kodama et al., 
2003; Leonard et al., 2005; Sengupta and Wasylyk, 2004; Wang et al., 
2012). However, hypoxia is also reported to reduce GR-dependent gene 
expression (Charron et al., 2009; Wagner et al., 2008). These contrasting 
findings indicate the presence of highly dynamic interactions between 
GR function and oxygen tension, possibly mediated through HIF-1α. 
Such interactions may influence adaptation to hypoxic environments. 
Recent advances in genomic technology provide a broader opportunity 
to study multiple levels of control of gene expression. GR occupies only a 
small subset of its potential binding sites across the genome in any single 
cell-type, resulting in strong cell-type specific control over GR function. 
Indeed, the overlap of Gc regulated gene expression profiles between 
observed cell lines is modest (John et al., 2009; Rogatsky et al., 2003; 
Wang et al., 2004). Epigenetic regulation mechanisms may be key to 
this, including nucleosome positioning, histone modification, and 
possibly DNA modification (Wiench et al., 2011a). 
More recent work has suggested that in turn glucocorticoid action 
may impact on HIF function. It appears that activated GR affects the 
stability of the VHL protein, and that as a result HIF-1α is stabilized, even 
under normoxic conditions. This suggests that some of the actions of 
glucocorticoids may in part be due to activation of HIF-1α action (Vet-
tori et al., 2017). 
Here, we use ChIP-seq to map the GR cistrome under normoxic and 
hypoxic conditions. Our findings reveal that enrichment of KLF4 motif 
under GR peaks in normoxia is lost in hypoxia, but KLF4 knockdown 
alone did not affect GR function. KLF4 is targeted by the hypoxia- 
induced microRNAs 103 and 107; both of which were indeed induced 
by hypoxia in our system. Mimetics to these microRNAs attenuated GR 
action, when used alone or in combination. Therefore microRNAs 103 
and 107 emerge as potent regulators of the GR in hypoxia. 
2. Materials and methods 
2.1. Antibodies and plasmids 
Anti-GR (clone 41) was from BD Biosciences (Oxford, UK); anti-GR 
(M-20 and H-300) and rabbit IgG were from Santa Cruz Biotech-
nology, anti-GR (HPA004248), anti-α-tubulin, hypoxia-mimetic defer-
oxamine and dexamethasone were from Sigma-Aldrich (Dorset, UK); 
anti-GR (24050-AP-1) was from Proteintech (Manchester, UK); anti- 
phospho-(Ser211)-GR was from Cell Signalling Technology (MA, 
USA); anti-H3K27ac was from Millipore; horseradish peroxidase con-
jugated anti-mouse and anti-rabbit were from GE Healthcare (Buck-
inghamshire, UK); fluorophore conjugated (Alexaflour 488) anti-mouse 
was from Invitrogen molecular probes (Paisley, UK); TAT3-luc a kind 
gift of Dr J Lluihi-Ineguez, University of California, San Franscisco, CA, 
USA. The NRE–luciferase reporter plasmid was obtained commercially 
(Stratagene). hGR pcDNA3 are a kind gift of Dr. M Norman, University of 
Bristol, Bristol, UK. GR deletants N500 and AF1 have been described 
previously (Berry et al., 2010). The HIF-1α expression vector was a kind 
gift from Dr. Costas Demonacos. 
2.2. Cell culture and maintenance 
Human cervical carcinoma cells and human embryonic kidney cells 
(HeLa and HEK; ECACC, Wiltshire, UK) were maintained at 37 ◦C with 
5% CO2 in a humidified atmosphere and cultured in DMEM medium 
supplemented with GlutaMAX and 10% FCS (Invitrogen, Paisley, UK). In 
order to ensure no residual Gcs were present during experiments, cells 
were grown in media supplemented with 10% charcoal dextran stripped 
serum (Invitrogen) for 24 h prior to treatment. For experiments con-
ducted under anoxic culture conditions, HeLa and HEK cells were 
transferred to an anaerobic chamber (Bactron anaerobic chamber, 
Sheldon Manufacturing, Cornelius, OR, USA) supplied with a gas 
mixture of 5% CO2:5% H2:90% N2, which removes residual oxygen by 
passing over a palladium catalyst. Exposures to hypoxia were generated 
using continuous gassing of a sealed chamber containing 1% oxygen 
with 5% CO2 in nitrogen. Oxygenation was assessed by an oxygen meter 
(measurement accuracy, ±1%; WPI Inc. Sarasota, FL). 
2.3. Reporter gene assay 
Cells were transfected with 2 μg of TAT3-luciferase and 0.5 μg of 
CMV-Renilla luciferase reporter using FuGENE 6 (3:1 Fugene: DNA 
ratio, Roche Diagnostics, Indianapolis, IN, USA). After 24 h, cells were 
transferred to medium containing charcoal dextran-stripped serum, 
treated before lysis, and then assayed for luciferase activity following 
the manufacturer’s instructions (Promega). To control for transfection 
efficiency, cells were taken from a single pool and divided into different 
treatment conditions. All firefly luciferase readings were normalised to 
Renilla luciferase. 
2.4. Quantitative RT-PCR 
After dexamethasone (Sigma-Aldrich, D4902) treatment, total RNA 
was prepared from HeLa cells using RNeasy Mini Kit with on-column 
DNase I digestion (Qiagen, Valencia, CA, USA) and cDNA was syn-
thesised using High Capacity RNA to cDNA kit and analyzed using Power 
SYBR Green PCR Master Mix (Applied Biosystems, CA, USA). GAPDH 
was used as an endogenous control. The expression of KLF4 level was 
detected using TaqMan gene expression assay (Applied Biosystems, 
Foster City, CA, USA). 18S rRNA was used as an endogenous control for 
multiplex reactions. Expression levels were calculated using the 
comparative Ct method, normalising to the control. 
2.5. Immunoblot analysis 
Cells were lysed in NETN buffer (0.5% NP-40, 1 mM EDTA, 50 mM 
Tris-Cl (pH 8.0), NaCl (120 mM) containing protease (Calbiochem, San 
Diego, CA, USA) and phosphatase inhibitors (Sigma-Aldrich). Proteins 
were separated by SDS gel electrophoresis and transferred to 0.2 μM 
nitrocellulose membranes (Bio-Rad Laboratories, Hertfordshire, UK) 
overnight at 4 ◦C. Membranes were blocked for 6 h (0.15M NaCl, 1% 
milk and 0.1% Tween 20) and incubated with primary antibodies 
(diluted in blocking buffer) overnight. Following three washes (88 mM 
Tris, pH 7.8, 0.25% dried milk, and 0.1% Tween 20), membranes were 
incubated with a species-specific horseradish peroxidase–conjugated 
secondary antibody (in wash buffer) for 1 h at room temperature and 
washed a further three times, each for 10 min. Immunoreactive proteins 
were visualised using enhanced chemiluminescence (ECL Advance, GE 
Healthcare). All primary immunoblot images are available in Fig. S5. 
2.6. Immunofluorescence 
Cells were washed twice in PBS then fixed with 4% para-
formaldehyde (PFA) for 30 min, then permeabilised (0.02% Triton X- 
100 in PBS) for 30 min at room temperature (RT). Fixed cells were 
blocked (1% FCS, 0.01% Triton X-100 in PBS) and incubated with pri-
mary antibody overnight at 4 ◦C. After three washes with PBS cells were 
incubated in secondary antibody for 2 h. After incubation with Hoechst 
for 5 min, coverslips were washed three times with PBS and mounted 
using Vectashield aqueous HardSet mountant (Vector Laboratories, 
Peterborough, UK). Images were acquired on a Delta Vision RT (Applied 
Precision) restoration microscope using a 60x/1.42 Plan Apo objective 
and the Sedat filter set (Chroma 89000) and collected using a Coolsnap 
HQ (Photometrics) camera with a Z optical spacing of 0.5 μm. Raw 
images were deconvolved using the Softworx software and maximum 
intensity projections of deconvolved images processed using ImageJ. 
2.7. Co-immunoprecipitation 
HeLa cells transfected with HIF-1α, treated with vehicle or 
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dexamethasone for 1 h then lysed in RIPA buffer containing protease and 
phosphatase inhibitors. GR was immunoprecipitated using GR-antibody 
(or IgG as a control) complexed to Protein A Sepharose beads overnight 
at 4 ◦C. Beads were collected by centrifugation (20 s at 2000g), washed 
three times with PBS and then boiled in SDS loading buffer prior to 
electrophoresis. 
2.8. Chromatin immunoprecipitation (ChIP) 
ChIP assays were performed as per standard protocols (Elsby et al., 
2009). Cells were treated with either 100 nM dexamethasone or DMSO 
as control for 1 h, and then cross-linked with 1% formaldehyde at room 
temperature for 10 min. The reaction was quenched by adding 0.125 M 
glycine for 5 min. Following collection by low-speed centrifugation 
(700 g), nuclei were lysed (50 mM Tris-HCl pH 8.1, 10 mM EDTA, 1% 
SDS and protease inhibitor) and sheared twice by probe sonication 
(SONICS VCX130) with energy more than 50% (12 s on, 40sec off), 
followed by water sonication using Bioruptor (Diagenode) for 40 min, at 
4 ◦C (high level, 30 sec on, 30 sec off). 
The size of sheared DNA fragments were between 100 bp and 500 bp, 
with most approximately 200 bp. Immunoprecipitated chromatin (IP) 
was 1 in 10 diluted using IP dilution buffer (16.7 mM Tris-HCl pH 8.1, 
1.2 mM EDTA, 167 mM NaCl, 0.01% SDS, 1.1% Triton X-100 and pro-
tease inhibitor). Each IP was incubated in 3 μg GR antibody (1 μg 
HPA004248, 1 μg M-20, 1 μg H-300), or 3 μg YFP antibody as control at 
4 ◦C overnight, and then Dynabeads Protein G (Invitrogen) added for 4 h 
with slow rotation. For the KLF4 knockdown ChIP experiment, pre-
cleared IP was added with either 2 μg GR antibody (24050-1-AP; Pro-
teintech, Manchester, UK), or 20 ng of Drosophila Spike-In chromatin 
and 2 μg of corresponding Spike-In antibody (Active Motif, La Hulpe, 
Belgium) as control. Following overnight incubation, 10 μl of equili-
brated MagReSyn® Protein G beads were added rotating at 20 rpm at 
4 ◦C for 2 h. 
Subsequently, the beads were washed twice with Buffer 1 (20 mM 
Tris-HCl pH 8.1, 2 mM EDTA, 50 mM NaCl, 0.1% SDS, 1% Triton X-100 
and protease inhibitor), once with Buffer 2 (10 mM Tris-HCl pH 8.1, 1 
mM EDTA, 250 mM LiCl, 1% NP40, 1% sodium deoxycholate and pro-
tease inhibitor) and twice with TE buffer (10 mM Tris-HCl pH 8.0, 1 mM 
EDTA pH 8.0 and protease inhibitor). Chromatin was eluted in 1% SDS 
and 100 mM NaHCO3, and then incubation in 200 mM NaCl at 65 ◦C 
overnight to reverse the crosslinks. The DNA was cleaned up using a 
MinElute PCR Purification Kit (28006; Qiagen, Valencia, CA, USA). 
Real-time quantitative PCR was performed using primers specific to 
TSC22D3, FKBP5, MT1X, IL6ST and BATF using SYBR Green detection 
system. 
2.9. Sequencing and ChIP-seq analysis 
GR ChIP-seq in HeLa cells were performed on an Illumina HiSeq 
2000 genome analyzer by BGI, and the alignment of 49 bp sequences 
was based on the Human Reference Genome (assembly hg19, NCBI Build 
37.1, February 2009) using SOAP version 2.21 (Li et al., 2009). Reads 
with SOAP alignment quality values less than 20 were removed. The 
unmapped and mapped reads are deposited with ArrayExpress 
(E-MTAB-1851). For each sample, 9.5 M equal best matching reads were 
used for peak calling; enriched regions were identified by comparing 
ChIP sample reads with input sample reads, using the MACS peak caller 
version 1.4.0 (Zhang et al., 2008). The region was defined as a peak 
where p-value < 1e-5. 
2.10. Heatmap generation 
In different samples GR binding regions were used as targets to 
generate the heatmaps of ChIP-seq data. The comparative analysis was 
completed using seqMINER_1.3.3e software (Ye et al., 2011). Read 
enrichment values within ± 5 kb of GR binding regions was assigned to 
each 25bp bin, which were linearly normalised to sequencing reads of 
control. KMeans was applied for clustering to four groups. 
2.11. STRING 10 analysis 
MicroRNA103–3p/107 targets were defined using Targetscan 
(Agarwal et al., 2015). The STRING database version 10.5 (Szklarczyk 
et al., 2017) was used to identify GR interactors within the network of 
Targetscan-defined list of microRNA targets. Interaction sources were 
limited to experimental evidence and databases. Line thickness indicates 
confidence of interaction. 
2.12. Motif analysis 
Motif discovery used RSAT (Thomas-Chollier et al., 2012). Se-
quences of 200bp centered on each GR summit were analyzed using 
peak motifs ChIP-seq analysis. Two of the available methods were 
applied, oligo-analysis and position-analysis, using the default back-
ground (Markov model adapted to sequence length). Discovered motifs 
were ranked by corrected p value or ‘Sig’ value. ‘Sig’ is defined as: ‘Sig’ 
= -log10 (e value), where e is the expected number of false positives 
corresponding to the motif p value. Pearson’s correlation and motif 
width normalised correlation indicate the similarity of the discovered 
motifs to the transcription factor reference databases (Jaspar, RSAT). 
2.13. Gene ontology (GO) analysis 
GO function analysis of peak-related genes was performed using 
GREAT version 2.0.2 (McLean et al., 2010). Following the use of the 
default gene regulatory definition option GREAT identified binding re-
gions up to 5 kb upstream, together with 1 kb downstream to each gene. 
The regulatory region was then extended in both directions up to 1000 
kb. Core peaks were selected for analysis using false discovery rate 
(FDR) less than 0.1. 
2.14. CEAS analysis 
The genomic distribution the of binding sites was determined using 
CEAS (Shin et al., 2009). Promoter regions were defined as starting 3 kb 
upstream from RefSeq transcription start sites (TSS), binding regions >
3k bp away from TSS was considered to be distal intergenic. 
2.15. Quantitative RT-PCR analysis of microRNAs 
The miRcury LNA™ Universal RT microRNA PCR system (Exiqon) 
was applied to measure expression of microRNAs, using LNA enhanced 
specific primer sets for either hsa-miR-103a-3p (target sequence: 
AGCAGCAUUGUACAGGGCUAUGA), or hsa-miR-107 (target sequence: 
AGCAGCAUUGUACAGGGCUAUCA). Relative amount of individual 
microRNA was normalised to 5S rRNA. The fold change in microRNA 
expression was calculated using the comparative Ct method. 
2.16. KLF4 knockdown via siRNA transfection 
siRNA transfections were carried out using two pre-designed 
Silencer® Select siRNAs specific for KLF4 (s17794 and s17793, 
Ambion Life Technologies, Austin, TX, USA). Silencer® Select Negative 
Control No. 1 siRNA (Ambion-4390844) was used as a negative control. 
Lipid and siRNA complexes were prepared using DharmaFECT Trans-
fection Reagent 1 (GE Dharmacon, Lafayette, CO, USA) in OptiMEM 
media (Gibco™ Thermo Fisher Scientific, Waltham, MA, USA) and 
diluted into 10 cm plates containing HeLa cells at a concentration of 5 ×
105 cells/plate 24 h prior to transfection. Final siRNA concentrations 
were set to 25 nM, and cells were transfected for a total of 72 h. 
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2.17. Statistical analysis 
Data were analyzed using SPSS in multiple samples. Multiple means 
were compared by one-way ANOVA followed by Bonferroni post hoc test 
or Kruskal-Wallis followed by Dunn’s post hoc test where Gaussian dis-
tribution could not be assumed. For comparison of two groups a Stu-
dent’s t-test for independent samples was used. For non-parametric data 
a Mann-Whitney U test was used. Statistically significant was considered 
as p-value < 0.05. 
3. Results 
3.1. Hypoxia rewires the GR cistrome 
Culture in hypoxia or treatment with a hypoxia-mimetic deferox-
amine induced Gc resistance to a simple, transfected reporter gene 
(Fig. 1A). We confirmed the conditions induced stabilization of HIF-1α 
protein (Fig. 1B), but were unable to find evidence for a direct inter-
action between GR and HIF-1α by co-immunoprecipitation (Fig. 1C, 
Fig. S1). 
To identify genome-wide binding of GR in response to dexametha-
sone in normoxic or hypoxic culture conditions, we took an unbiased 
ChIP-seq approach. We identified 595 core GR binding sites with high 
confidence that were dependent on ligand activation (Fig. 1D). There 
were differences in GR recruitment dependent on oxygen tension, with 
some sites lost, and others gained in hypoxic conditions (Fig. 1D). 
Identified GR binding sites were validated by ChIP-PCR. In line with the 
ChIP-seq analysis, ChIP-PCR shows reduced GR binding at TSC22D3 (or 
GILZ), equal GR binding at FKBP5 and increased binding at MT1X 
promoters in response to hypoxia (Fig. 1E). 
Fig. 1. Hypoxia rewires the GR cistrome. (A) HeLa cells were transfected with 2 μg TAT3-luc, cultured under normoxic conditions in the presence or absence of the 
hypoxia mimetic deferoxamine (100 μM), or in an anoxic chamber then treated with dexamethasone (Dex) for 16 h prior to lysis and luciferase assay. (B) Cells 
cultured in normoxia, anoxia, treated with deferoxamine or transiently transfected with HIF-1α were lysed and immunoblotted for HIF-1α or tubulin as a loading 
control. (C) Cells treated with deferoxamine were incubated with or without 100 nM dexamethasone for 1 h, lysed, immunoprecipitated for GR, and then immu-
noblotted for HIF-1α. (D) HeLa cells were cultured in either normoxia or hypoxia overnight, and GR cistrome identified by ChIP-seq. The heatmap shows binding 
peak intensity of 595 core GR binding sites aligned according to their summits. Three clusters were applied, and 5 kb upstream and 5 kb downstream regions around 
the summit are plotted. (E) UCSC browser tracks for TSC22D3, FKBP5 and MT1X in normoxia and hypoxia, where the y axis of each track represents the coverage by 
non redundant and extended reads from MACS analysis. These RefSeq annotated genes are shown and the gene direction indicated by an arrowhead. GR binding sites 
were quantified by ChIP-qPCR. Graphs depict fold enrichment of immunoprecipitated GR in response to treatment with dexamethasone over vehicle treated control 
and show mean ± S.D. from three independent experiments. *p < 0.01, NS: not significant. 
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3.2. Hypoxia retains similar GR distribution with different gene function 
Hypoxia did not alter the average signal intensity of GR binding in 
response to dexamethasone, again implying no major effect on GR 
expression or global alteration in GR function (Fig. 2A). The core 200bp 
regions centered on GR peak summits were subsequently analyzed using 
CEAS. We found more than 50% of the GR binding events located in 
distal intergenic regions (Fig. 2B, Table S1), in agreement with previous 
observations (Uhlenhaut et al., 2013). There was no significant differ-
ence in the location of GR binding sites in relation to coding regions 
between hypoxia and normoxia, and as expected the peaks of GR 
binding regions revealed enrichment of the consensus glucocorticoid 
responsive element (GRE) motif under both conditions (Fig. 2C). 
We further analyzed likely genes regulated by the GR cistromes 
under normoxic and hypoxic conditions using GREAT (McLean et al., 
2010). Hypoxia depleted GR target genes involved in gene ontology 
(GO) biological processes, including ‘inflammatory response’ (Fig. 2D, 
Table S2), and increased targets genes involved in the ‘response to ox-
ygen’ (Fig. 2E). Disease ontology analysis identified several 
hypoxia-associated genes with significant terms involved in inflamma-
tory diseases, e.g. arthritis (Fig. 2F, Table S3). 
3.3. Hypoxia regulates H3K27 acetylation at GR binding sites 
As oxygen tension specifically drives the distribution of GR binding 
sites, we compared the number of genes regulated in either normoxia or 
hypoxia, and found only 175 genes in both conditions (Fig. 3A). The 
majority of the sites identified in hypoxia were not seen in normoxia. 
This prompted more detailed examination at specific GR target sites, 
starting with the well-characterised PER1 locus. This analysis revealed a 
reduction in GR binding under hypoxic conditions (Fig. 3B), consistent 
with the observed loss of GR transactivation (Fig. 1A, D). To analyze the 
functional significance of the GR binding sites identified under normoxic 
conditions, we overlaid the GR cistrome with the histone H3K27ac and 
co-activator p300 ChIP-SEQ data, previously defined by the ENCODE 
project (GEO accessions GSM733684 and GSM935500). There was clear 
overlap between GR binding and p300, and also with enrichment of 
H3K27ac in 209 of the 595 high-confidence GR binding sites (Fig. 3C; 
Cluster 1). The p300 co-activator is a powerful mediator of GR trans-
activation, and brings histone acetylation enzymatic activity to the GR 
bound sites (Guo et al., 2017). In contrast, more than half of the GR 
binding sites showed negligible enrichment for the co-activator, and 
active histone mark (Fig. 3C; Cluster 2). This suggests identification of 
Fig. 2. Hypoxia retains similar GR distribution with different gene function. (A) Average signal intensity of all core GR binding events for normoxia (blue) and 
hypoxia (orange). (B) Pie charts represent the genomic distribution of Gc induced GR-bound regions. (C) Motif discovery analysis identifies the enrichment of 
glucocorticoid responsive elements (GRE). (D, E) The analysis of GR binding regions and the corresponding gene ontology of their associated genes were carried out 
using GREAT. Significantly enriched terms from the biological process category are illustrated as bar charts for normoxia or hypoxia. (F) List of genes associated with 
arthritis identified as being regulated by GR binding events specifically in hypoxia. 
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different classes of GR binding sites, potentially both enhancer and 
repressor elements (Fig. 3C). 
To test if the differential acetylation of H3K27 was seen there, index 
target GR binding sites related to the GR-transactivated target genes 
TSC22D3, FKBP5 and MT1X were analyzed by ChIP-PCR (Fig. 3D). 
Indeed, these data showed that there was a loss of acetylated H3K27 in 
response to dexamethasone treatment in hypoxia for the TSC22D3 GR 
element, and in contrast a gain at the MT1X site. Hypoxia had no effect 
on H3K27 acetylation at the GR binding site on FKBP5. These changes in 
post GR activation chromatin state are predicted from the corresponding 
changes in GR recruitment to these sites (Fig. 1E), and reinforce the 
importance of H3K27ac as a mark of active chromatin at GR binding 
sites (Fig. 3C; Cluster 1). The different composition of DNA-bound 
complexes is illustrated by the analysis of co-binding between the GR 
and the co-modulator, and histone acetyltransferase p300, and that of its 
chromatin mark H3K27ac (Fig. 3E). The sites bound both by GR and 
p300 are far more likely to have an activating chromatin mark 
(H3K27ac) that those bound by GR alone, which may be a surrogate to 
identify genes repressed by GR. 
3.4. Hypoxia eliminates the enrichment of KLF4 motif at GR binding sites 
DNA motif analysis (RSAT) in the 200bp sequences centered on the 
summit of GR binding region identified GRE, ARE, SP1, AP1 and NF1C 
motifs in both normoxic and hypoxic groups (Fig. 4A and B, Figs. S2 and 
S3). We noted that potential KLF4 motifs were represented only in 
normoxia (Fig. 4A, Fig. S2), whereas FOXL1 motifs were only seen under 
hypoxic GR binding events (Fig. S3). We found no effect of hypoxia on 
transcript abundance of SP1, NFIC or FOXL1; however, there was a 
modest reduction in KLF4 transcript in hypoxia (Fig. 4C). Further 
analysis revealed loss of KLF4, but not SP1 proteins under hypoxia 
(Fig. 4D), identifying hypoxia regulation of KLF4. 
3.5. MicroRNAs regulate the impaired GR transactivation in hypoxia 
To further study the role of KLF4 in the GR cistrome, UCSC browser 
gene tracks for candidate genes were examined according to the defined 
histone H3K27ac and co-activator p300 ChIP-seq data, as well as pre-
viously published KLF4 ChIP-seq data (GSM447584 (Lister et al., 2009)). 
Fig. 3. Hypoxia regulates H3K27 acetylation at GR binding sites. (A) A Venn diagram describes overlap of GR cistromes in normoxia (green) and hypoxia 
(yellow). (B) UCSC browser track for GR binding at the PER1 locus, where the y axis depicts the coverage by non redundant and extended reads from MACS analysis. 
(C) Cistromes for H3K27ac, and p300 in HeLa cells were aligned with GR binding peaks. Two groups were observed, one showing strong overlap amongst the three 
signals, and one cluster showing negligible overlap. (D) H3 acetylation levels of TSC22D3, FKBP5 and MT1X were quantified by ChIP-qPCR, in response to dexa-
methasone treatment. Graphs illustrate fold enrichment of immunoprecipitated H3K27ac in response to treatment with dexamethasone over vehicle treated control. 
Mean ± S.D. from three independent experiments. *p < 0.01, NS: not significant. (E) A Venn diagram summarises the overlap of the three cistromes, where GR is 
shown in green, p300 in blue and H3K27ac in yellow. 
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Interestingly, both overlapping GR/KLF4 binding sites (IL6ST) and 
adjacent GR/KLF4 binding sites (BATF) (Fig. 5A) were observed. 
Consistent with this, qRT-PCR showed a reduction of Gc induced GR 
transactivation of both IL6ST and BATF in hypoxia (Fig. 5B). 
To determine if hypoxia impaired GR transactivation is due to loss of 
KLF4 expression, an independent KLF4 knockdown study was performed 
(Fig. 5C). Subsequently, ChIP-qPCR was completed using IL6ST and 
BATF primers targeting the GR binding sites (Fig. 5D). Unexpectedly, 
dexamethasone-induced GR binding activity to the IL6ST and BATF sites 
was unchanged after depletion of KLF4 (Fig. 5D). KLF4 is known to be a 
target for microRNAs 103 and 107 (Chen et al., 2012) and both of these 
microRNAs are induced by hypoxia in a variety of cell types (Kul-
shreshtha et al., 2007). Therefore, the expressions of both microRNA103 
and 107 were measured, and indeed, in this cell system, both microRNAs 
were significantly induced by hypoxic culture (Fig. 6A). Furthermore, 
overexpression of microRNA103 and 107 mimetics in normoxia 
impaired GR transactivation of both IL6ST and BATF (Fig. 6B), reca-
pitulating the effect of hypoxia culture. These results suggest that KLF4 
alone is not sufficient to explain the hypoxia regulation of GR chromatin 
engagement. The microRNAs 103 and 107 are closely related, and share 
a major overlap in target gene preference. 
3.6. MicroRNA 103 and 107 regulation of GR transactivation function 
The identification of the two microRNAs as novel regulators of GR 
transactivation prompted us to investigate transactivation domain 
function. We moved to HEK293T cells, which are insufficient in 
endogenous GR expression to drive endogenous target gene induction 
(Fig. S4). We analyzed the expression of the index target gene TSC22D3 
(or GILZ), identified as a transactivated target gene sensitive to hypoxia, 
cluster 1 in Fig. 1D. Importantly, GR induction of the TSC22D3 gene 
requires only the AF2 domain of the GR, permitting analysis of the role 
of GR AF1 in mediating inhibition by the microRNAs (Fig. 6C) (Hong 
et al., 1997; Teyssier et al., 2006). However, although the microRNA 
103/107 opposed full-length GR transactivation of TSC22D3, they 
lacked the same effect when transactivation was driven by a GR lacking 
the AF1 domain, suggesting that the inhibitory effect required the 
presence of the GR N terminal transactivation domain (Fig. 6D). 
Fig. 4. Hypoxia eliminates the enrichment of KLF4 motif at GR binding sites. (A, B) Motifs under peaks of GR binding in normoxia and hypoxia were analyzed 
using RSAT. The top 6 GR binding motifs identified were ranked by adjusted p value, ‘Sig’. Equally ranking motifs were ordered by decreasing percentage of GR 
binding regions containing the motifs. The degree of similarity between discovered motifs and matching motifs in JASPAR were measured by Pearson correlation 
coefficient. N.D. refers to the motifs were not discovered previously. (C) HeLa cells were cultured in either normoxia or hypoxia overnight. RNA samples were 
purified and the expression of SP1, NFIC, FOXL1 and KLF4 transcripts determined. (D) Protein samples were extracted from HeLa cells and KLF4 and SP1 expression 
measured by immunoblotting. Immunoblots show samples from three independent experiments. Immunoreactive bands for SP1 and KLF4 were quantified using 
Image J software, normalised to tubulin expression and then represented as a fold change over normoxia cultured cells. Graphs show mean ± S.D. of experiments 
repeated three times. **p < 0.01, *p < 0.05. 
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Fig. 5. MicroRNAs regulate the impaired GR transactivation in hypoxia. (A) Cistrome for KLF4 was also aligned with GR peaks, highlighted IL6ST and BATF as 
genes under common regulation. Individual UCSC browser gene tracks for IL6ST and BATF are shown with GR, KLF4, H3K27ac and p300 peaks. (B) Cells were 
cultured in normoxia or hypoxia overnight, then treated with control or 100 nM dexamethasone for 4 h before harvest. Expression levels of either IL6ST or BATF 
transcript were measured by qRT-PCR. Graphs show the fold change of transcripts in response to treatment with dexamethasone compared to control. Mean ± S.D. n 
= 3. (C) HeLa cells were transfected with KLF4-specific siRNAs (siR93 and 94) and a negative control siRNA for 72 h. KLF4 knockdown efficiency was measured by 
qRT-PCR. Representative data are shown as mean ± S.E.M. n = 8. (D) Following KLF4 knockdown, cells were treated with dexamethasone (Dex) or DMSO as the 
vehicle. ChIP-qPCR was performed using IL6ST and BATF specific primers. CT values were normalised to Spike-In chromatin. Data are presented as fold enrichment 
over the Veh-treated control group. Data are shown as mean ± S.E.M. n = 4. ****p ≤ 0.0001, ***p ≤ 0.001, *p < 0.05. 
Fig. 6. MicroRNAs impact on GR trans-
activation function. (A) Cells were cultured 
in normoxia or hypoxia overnight, and the 
expression of both microRNAs 103 and 107 
(miR103 and miR107) measured by qRT- 
PCR. Mean ± S.D. n = 3, *p < 0.05. (B) 
Cells were transfected with pre-microRNA 
control, or 50 nM mimics for either hsa- 
miR-103a-3p or hsa-miR-107, or both 
together, for 48 h. Cells were then treated 
with 100 nM dexamethasone or DMSO for 4 
h prior to RNA purification. Expression 
levels of either IL6ST, or BATF transcript 
were measured by qRT-PCR. Data are shown 
as fold change of transcripts in response to 
dexamethasone treatment over DMSO con-
trol. Mean ± S.D. n = 3. **p < 0.001, *p <
0.05. (C, D) HEK293T cells were transfected 
with either control sequences (PreM), or 
microRNA mimic (MiRs) for 48 h. Following 
transfection with ΔAF1 (GR construct lack-
ing N-terminus), or full-length GR overnight, 
cells were treated with vehicle or 100 nM 
dexamethasone (Dex) for 4 h before harvest. 
RNA samples were purified and analyzed by 
qRT-PCR for the TSC22D3 mRNA. Data are 
shown as mean ± S.E.M. n = 3. ***p <
0.001, **p < 0.01, *p < 0.05.   
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These two microRNAs target many genes in a functional, coherent 
network related to the glucocorticoid receptor (Fig. 7A and B, Tables S4 
and S5), including the GR co-modulators CARM1, and NCOA2. As can be 
seen from the predicted genetic targets of the two microRNAs KLF4 is a 
direct target, which is supported by earlier work showing a loss of KLF4 
protein in cells expressing the microRNA 103/107 (Chen et al., 2012). 
Therefore, it appears that hypoxic stabilization of HIF-1α drives 
expression of the microRNA 103/107, and that this intermediary step 
leads to loss of KLF4 protein expression. However, the KLF4 protein loss 
is associated with the loss of GR function, rather than being the sole 
cause of it. 
3.7. Hypoxia regulates GR function through transactivation domain 
The earliest response of the GR to ligand activation is phosphoryla-
tion, a step required for full activity of the activation domains on some 
enhancers and nuclear translocation to permit engagement with target 
sites in the genome. These two steps were investigated under hypoxic 
conditions. Neither Ser211 phosphorylation (Fig. 8A), nor nuclear 
accumulation (Fig. 8B) was affected by hypoxia, implying a post-nuclear 
event; in keeping with the differential engagement with target sites, 
rather than loss of GR binding to DNA. 
As the two transactivation domains of the GR may be differentially 
impacted by the microRNA 103/107. Therefore, we wanted to deter-
mine if there were domain-dependencies in the hypoxia response. 
Initially examined four GR transactivated genes, which have been 
shown a differential recruitment of GR in hypoxia (Fig. 8C). Interest-
ingly, we saw a loss of GR transactivation in all four genes, despite the 
previously observed variation in GR recruitment, and GR site H3K27 
acetylation. This result further suggests that the GR transactivation 
domains may be affected by oxygen tension, as well as the selection of 
binding sites. This diversity of mechanisms may explain the previous, 
contradictory findings in the literature. In addition, we selected two 
index GR transrepressed genes, inflammatory cytokines IL-6 and IL-8 
(Fig. 8C). The lack of impact of hypoxia on GR transrepression of IL-6 
and IL-8 further supports a role for hypoxia in regulating GR trans-
activation, independently of GR transrepression. 
Because we had evidence that the GR AF1 domain was the target for 
the microRNAs (Fig. 6D), we further tested the function of the two GR 
transactivation domains separately using a simple reporter gene capable 
to responding to either domain in isolation (Fig. 8D). Loss of the ligand- 
binding domain resulted in a constitutive transactivating molecule 
sensitive to both anoxia and, the hypoxia mimetic deferoxamine. 
Strikingly, loss of the N terminal AF1 transactivation domain attenuated 
the inhibitory effect of the hypoxia mimetic, although anoxia still had a 
profound inhibitory effect. These results highlight an additional mech-
anism whereby hypoxia regulates GR transactivation through AF1 
domain. As this is the same domain affected by the microRNAs 103 and 
107 (Fig. 6D), it provides evidence that the hypoxia induction of the 
microRNAs is a plausible mechanism resulting in an AF1-specific defect 
in GR transactivation. 
4. Discussion 
Gcs exert a broad spectrum of metabolic and immune regulatory 
effects through activation of the near-ubiquitously expressed GR (Yang 
et al., 2012). The mechanisms responsible for conferring cell-type 
specificity of action are emerging, with up to 90% of GR binding sites 
being cell specific (Wiench et al., 2011a). This degree of specificity can 
be directed by epigenetic regulation of changes in accessibility of 
cis-elements (Wiench et al., 2011b). The cellular environment is also 
important for regulating responses, e.g. at sites of inflammation. This 
may be explained in part by recent observations that proinflammatory 
signalling regulates the GR cistrome, opening new sites and closing off 
others (Uhlenhaut et al., 2013). Sites of inflammation differ in several 
respects from healthy tissue, but amongst the changes consistently 
observed is the reduction in oxygen tension, due to bacterial and im-
mune cell oxygen consumption (Oliver et al., 2009). Indeed, macro-
phages are specifically adapted to migrate towards hypoxia, and utilise 
primarily glycolytic ATP generation which is not dependent on abun-
dant oxygen availability (Garedew et al., 2010; Ruiz-Garcia 2011). 
Previous reports yielded conflicting results on the effects of hypoxia on 
Gc action, possibly due to methodological differences, and reliance on a 
limited number of end-points. 
Our initial studies showed a marked reduction in GR transactivation 
of a simple reporter gene with consensus GRE elements. Our failure to 
detect physical interaction between the major hypoxia responsive 
transcription factor, HIF-1α, suggested that the mechanisms of hypoxia 
Fig. 7. MicroRNAs regulate a functional network of genes related to the glucocorticoid receptor. (A) The full list of microRNA103 and 107 target genes was 
analyzed by STRING10 in order to identify connections with the glucocorticoid receptor. A functional and highly interconnected network was identified, which is 
depicted. The full list of target genes used for the analysis is in Table S5. (B) The closest, functional connections between the microRNA 103/107 targeted gene 
network, and the glucocorticoid receptor (NR3C1) identified by STRING10 analysis are depicted. These include the GR co-modulators CARM1 and NCOA2. 
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adaptation are more complex and diverse, and so we undertook a 
genome-wide analysis of GR binding. We found most GR binding events 
were not in the proximal promoter regions of coding sequences, as re-
ported before, and that peaks of GR-binding sites were evenly distrib-
uted between upstream and downstream sequences (So et al., 2007). 
Remarkably, hypoxia opened a new GR cistrome, with a number of GR 
binding sites shared in common with normoxic conditions. Nearly 50% 
of GR binding sites were lost in the transition to hypoxia, indicating the 
re-programming of the GR cistrome in response to changes in ambient 
oxygen tension. This specificity of effect, which may be further influ-
enced by cell-type specific regulatory mechanisms, potentially explains 
the discrepant findings reported to date in the literature (Charron et al., 
2009; Kodama et al., 2003; Leonard et al., 2005; Sengupta and Wasylyk, 
2004; Wang et al., 2012). 
For the first time, we identified GR cistrome-regulated genes in both 
normoxia and hypoxia. Using GREAT analysis, we found normoxic GR 
binding sites were strongly associated with genes encoding components 
of the inflammatory response and apoptosis. Strikingly, hypoxia rewires 
the GR cistrome. Gene ontology analysis identified the terms of cellular 
response to oxygen tension and plasma membrane long-chain fatty acid 
transport, supporting a reprogramming of Gc action dependent on ox-
ygen tension (McLean et al., 2010). Interestingly, further disease 
ontology analysis revealed hypoxic GR-cistrome is associated with 
control of arthritis. As inflammatory arthritis is itself associated with 
reduced oxygen tension, this may point to an evolutionary adaptation to 
Gc signalling under hypoxic conditions to promote resolution of 
inflammation. 
Further analysis of GR binding sites by ChIP-PCR confirmed the 
predicted changes in GR recruitment, with coordinate changes in his-
tone H3K27ac status, suggesting productive engagement of target 
chromatin by the GR. Interestingly, target gene transactivation was 
consistently inhibited under hypoxic conditions, a change that was not 
predicted based on GR recruitment. This suggests the involvement of 
additional mechanisms explaining differential gene expression, possibly 
resulting from differential engagement of co-modulators, or additional 
effects conferred by other uncharacterised cis-elements. 
As predicted, motif discovery analysis identified GRE motifs under 
both normoxia and hypoxia. Surprisingly, although HIF-1α protein can 
bind in proximity to the GR under hypoxic conditions (Elsby et al., 
2009), HIF-1α motif was not shown among the most centrally enriched 
Fig. 8. Hypoxia regulates GR function through transactivation domain. (A) HeLa cells were cultured in either normoxia or hypoxia overnight, treated with 100 
nM dexamethasone (Dex) for 1 h then lysed and immunoblotted for GR and Ser211 phosphorylated GR. Tubulin was used as a loading control. Samples from two 
independent experiments are shown. (B) Cells cultured in normoxia or hypoxia overnight were treated with 100 nM dexamethasone (Dex) then fixed, and immu-
nolabelled for GR (white) expression. (C) Cells were cultured under normoxic or hypoxic conditions overnight, then treated with dexamethasone for 4 h prior to lysis. 
qRT-PCR was used to quantify GR transactivation of TSC22D3, MT1X, FKBP5, and PER1 and transrepression of IL-6 and IL-8. Graphs show mean ± S.D. of ex-
periments performed in triplicate and repeated three times. **p < 0.001, *p < 0.05, compared to normoxia. NS: not significant. (D) HEK293T cells expressing 2 μg 
TAT3-luc together with full length wild type receptor, GR ΔAF1 (lacking N-terminus), or GR N500 (lacking C-terminus) were cultured under normoxia with vehicle or 
100 μM deferoxamine (hypoxia), or cultured in anoxia overnight. Cells were incubated with dexamethasone for 16 h before luciferase assay. Graph depicts mean ± S. 
D. and is representative of at least three independent experiments. *p < 0.05 compared to normoxia. 
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motifs associated with hypoxic GR-cistrome. Instead, hypoxia resulted 
in less Kruppel-like factor 4 (KLF4) consensus sequences associated with 
GR binding sites, and increased abundance of FOXL1 consensus sites. 
This led us to focus on these two transcription factors as potentially 
involved in modulating GR function in hypoxia. The KLF4 cistrome 
showed some overlap with the GR cistrome, with both adjacent and 
overlapping target genomic sequences being identified, potentially 
indicating a role for KLF4 as a pioneer, or co-binding factor. Previous 
studies have identified a critical role for AP1 transcription factor in 
opening genomic binding sites to the GR (Biddie et al., 2011). However, 
in our analysis we did not detect a change in AP1 site enrichment 
dependent on oxygen tension. 
KLF4, a zinc finger transcription factor, is expressed in epithelia 
(Shields et al., 1996). It has been defined to play an important role to 
regulate cell proliferation, migration and differentiation (Ghaleb et al., 
2011). Interaction between GR and KLF4 has been observed in vivo, 
where corticosteroid treatment, and expression of KLF4 co-ordinately 
accelerated skin barrier function acquisition, and it was shown that 
genes regulated by GR and KLF4 significantly overlap (Patel et al., 
2006). Studies in colorectal carcinoma metastases revealed loss of KLF4 
protein expression driven by induction of two microRNAs 103 and 107 
(Chen et al., 2012). In our own studies presented here, we also observed 
a loss of KLF4 expression in hypoxia, which was associated with partial 
loss of the normoxic GR cistrome. Although KLF4 knockdown had no 
impact on GR recruitment to specific GREs, both of the microRNAs 
replicated the loss of GR transactivation seen in hypoxia. Probably, 
depletion of KLF4 alone is insufficient to replicate the hypoxia effect 
limiting GR recruitment to its recognition sites, and therefore additional 
mechanisms downstream of the microRNAs are likely to contribute. 
Indeed, the two closely related microRNAs target a broad network of 
genes with functional connections to GR. Amongst those with the closest 
links are the co-modulators CARM1, and NCOA2 (also known as SRC2, 
or GRIP1). Additional evidence for a GR transactivation domain mech-
anism comes from the GR domain deletion studies on both endogenous, 
and synthetic reporter genes. Here we see a requirement for the AF1 
domain to transmit the hypoxia/microRNA 103/107 signal. Now, the 
two GR transactivation domains are known to functionally interact, with 
some co-modulators such as NCOA2 binding to both, and inducing 
structural modification to the intrinsically-disordered AF1 domain 
(Weikum et al., 2017). Therefore, we propose that loss of co-modulators 
resulting from microRNA action, leads to a defective AF1 conformation 
which through allosteric interaction impairs the transactivation function 
of AF2. Deletion of the AF1, as in the ΔAF1 mutant, frees the AF2 from 
this negative effect, and permits transactivation even in hypoxia, likely 
through a spectrum of co-modulators that are not affected by the 
hypoxia-microRNA circuit. 
Therefore, we propose that the effector molecules for the change in 
Gc sensitivity, and target gene specificity, in hypoxia are these two key 
microRNAs. Moreover, our data suggest a complex system-wide effect of 
the microRNAs altering the expression of other transcription factors, 
including KLF4, as well as co-modulator genes, including CARM1, and 
NCOA2. Taken together, our data identified a reprogrammed GR cis-
trome induced by hypoxia (Fig. 9). In addition to the important role of 
cell-lineage specifying transcription factors, environmental sensing 
pathways such as those activated in hypoxia through the regulation of 
microRNAs are also involved in directing the GR cistrome, and subse-
quently in regulating GR function. This discovery opens up a novel 
mechanism to explain the clinically observed variation in Gc response in 
inflammation. 
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Fig. 9. A graphical overview of GR function 
under normoxia or hypoxia, and the role of 
microRNA 103/107 and KLF4. Left: GR trans-
activation of targets such as IL6ST, and BATF under 
normoxia, where the KLF4 binding motif was iden-
tified by our ChIP-seq analysis. Right: Hypoxia drives 
expression of both microRNAs 103 and 107 (miR103 
and miR107), which represses KLF4 expression (as 
shown in panel A), and inhibits multiple GR co- 
modulators, including CARM1 and NCOA2, as 
shown in panel B.   
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